论文部分内容阅读
为了探讨含Ｔ、Ｂ淋巴细胞双重激活表位的重组复合症疾抗原的免疫原性和保护作用，作者设计合成了编码恶性疟原虫红内期３个保护性抗原位点和２个外源性Ｔ细胞激活位点的复合基因ＨＧＦＣ，并构建了多连体复合基因ＨＧＦＣＡＣ。两种复合基因分别与表达载体ｐＷＲ４５０－１重组，并在大肠杆菌中表达出含外源蛋白和β－半乳糖苷酶部分氨基酸的融合蛋白（分子量分别为６５０００和７７０００），表达量为３５％。表达产物可与小鼠及兔抗恶性疟原虫抗体发生特异性免疫反应。用纯化的融合蛋白免疫家兔制备的免疫血清可特异地识别恶性疟原虫抗原，并对疟原虫体外生长有显著抑制作用。抑制程度与免疫血清浓度及作用时间呈正相关，在２０％浓度下作用７２小时，抑制率可达８２％，并引起疟原虫发育不良和死亡。研究结果说明，制备的恶性疟原虫重组复合抗原具有免疫原性和一定的免疫保护作用，可作为恶性疟疫苗候选物。
In order to investigate the immunogenicity and protective effect of recombinant complex disease antigen containing T and B lymphocyte dual activation epitopes, the authors designed and synthesized three protective antigenic sites and two exogenous T cell activation site of the complex gene HGFC, and the construction of the multi-gene complex gene HGFCAC. The two recombinants were recombined with the expression vector pWR450-1 respectively, and the fusion proteins containing 65% and 77000 amino acids of exogenous protein and β-galactosidase were expressed in E. coli with the expression level of 35% . The expression product can be specifically immunoreactive with mouse and rabbit anti-Plasmodium falciparum antibodies. Immunization of rabbits with the purified fusion protein immunized serum can be specifically identified Plasmodium falciparum antigens, and malaria parasites in vitro growth was significantly inhibited. The degree of inhibition was positively correlated with the serum concentration and duration of action, with a 72% inhibition at 20% concentration, with an inhibitory rate of 82%, causing malaloptoid dysplasia and death. The results show that the prepared recombinant Plasmodium falciparum antigen has immunogenicity and immune protection, and can be used as a candidate for falciparum malaria vaccine.